120 related articles for article (PubMed ID: 31113587)
1. Experience with Sorafenib in 3 Hospitals in Sao Paulo.
Camargo-Pinheiro-Alves R; Viera-Alves DE; Malzyner A; Gampel O; Almeida-Costa TF; Guz B; Poletti P
Ann Hepatol; 2019; 18(1):172-176. PubMed ID: 31113587
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
3. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
5. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
[TBL] [Abstract][Full Text] [Related]
6. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
Choi GH; Shim JH; Kim MJ; Ryu MH; Ryoo BY; Kang YK; Shin YM; Kim KM; Lim YS; Lee HC
Radiology; 2013 Nov; 269(2):603-11. PubMed ID: 23864102
[TBL] [Abstract][Full Text] [Related]
8. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
Zhao Y; Wang WJ; Guan S; Li HL; Xu RC; Wu JB; Liu JS; Li HP; Bai W; Yin ZX; Fan DM; Zhang ZL; Han GH
Ann Oncol; 2013 Jul; 24(7):1786-1792. PubMed ID: 23508822
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study.
Hsiao WD; Peng CY; Chuang PH; Lai HC; Cheng KS; Chou JW; Chen YY; Yu CJ; Feng CL; Su WP; Chen SH; Kao JT
BMC Gastroenterol; 2016 Apr; 16():50. PubMed ID: 27117280
[TBL] [Abstract][Full Text] [Related]
12. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
Zhang K; Sun X; Xie F; Jian W; Li C
J Cancer Res Ther; 2018 Jan; 14(1):196-200. PubMed ID: 29516985
[TBL] [Abstract][Full Text] [Related]
14. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
Sato Y; Nishiofuku H; Yasumoto T; Nakatsuka A; Matsuo K; Kodama Y; Okubo H; Abo D; Takaki H; Inaba Y; Yamakado K
J Vasc Interv Radiol; 2018 Aug; 29(8):1061-1067. PubMed ID: 29934260
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
Zhang Y; Fan W; Wang Y; Lu L; Fu S; Yang J; Huang Y; Yao W; Li J
Oncologist; 2015 Dec; 20(12):1417-24. PubMed ID: 26446238
[TBL] [Abstract][Full Text] [Related]
16. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
Liu KC; Hao YH; Lv WF; Jia WD; Ji CS; Zhou CZ; Cheng DL; Xu SB; Gao ZG; Su MX; Shi CS
Drug Des Devel Ther; 2020; 14():3461-3468. PubMed ID: 32904650
[TBL] [Abstract][Full Text] [Related]
17. Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib.
Zheng J; Shao G; Luo J
Clin Transl Oncol; 2014 Nov; 16(11):1012-7. PubMed ID: 24894839
[TBL] [Abstract][Full Text] [Related]
18. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
Li L; Gou CY; Li JY; Achakzai R; Li XH
Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
[TBL] [Abstract][Full Text] [Related]
19. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population.
Lee SW; Tung CF; Peng YC; Lien HC; Chang CS
J Dig Dis; 2020 Aug; 21(8):462-467. PubMed ID: 32472590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
